# Study of ESG406 in Adults With Solid Tumors

> **NCT06979674** · PHASE1 · RECRUITING · sponsor: **Shanghai Escugen Biotechnology Co., Ltd** · enrollment: 556 (estimated)

## Conditions studied

- Locally Advanced/Metastatic Solid Tumors

## Interventions

- **DRUG:** ESG406

## Key facts

- **NCT ID:** NCT06979674
- **Lead sponsor:** Shanghai Escugen Biotechnology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-04
- **Primary completion:** 2028-04
- **Final completion:** 2028-06
- **Target enrollment:** 556 (ESTIMATED)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06979674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06979674, "Study of ESG406 in Adults With Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06979674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*